Evidence map›Paper›PMID 39152491›Full record

ArticleClinical epigenetics2024

Triage performance of PAX1

Xiaojing Chen, Xitong Jin, Linghua Kong, Yuligh Liou, Pei Liu, Zhe Dong, Sijun Zhou, Bingli Qi, Jing Fei, Xiaoyan Chen and 6 more

Abstract readMulticenter Study
In one paragraph

Article in Clinical epigenetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. PAX1 and ZNF582 Methylation as a Triage Strategy in Cytologic and hrHPV+ Scrapings in Both Chinese and Dutch Cohorts.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Clinical significance ofFrontiers in cellular and infection microbiology · 2026
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Assessment ofFrontiers in oncology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Xiaojing ChenDepartment of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, 100730, China.
Xitong JinDepartment of Medical Laboratory, Beijing Origin-Poly Bio-Tec Co., Ltd., Beijing, 102600, China.
Linghua KongDepartment of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, 100730, China.
Yuligh LiouDepartment of Medical Laboratory, Beijing Origin-Poly Bio-Tec Co., Ltd., Beijing, 102600, China.
Pei LiuDepartment of Medical Laboratory, Beijing Origin-Poly Bio-Tec Co., Ltd., Beijing, 102600, China.
Zhe DongDepartment of Obstetrics and Gynecology, Peking University International Hospital, Beijing, 100000, China.
Sijun ZhouDepartment of Obstetrics and Gynecology, Inner Mongolia Autonomous Region People's Hospital, Hohhot, 010000, China.
Bingli QiDepartment of Gynecology, Cangzhou Central Hospital, Cangzhou, 061000, China.
Jing FeiDepartment of Obstetrics and Gynecology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, 310000, China.
Xiaoyan ChenDepartment of Obstetrics and Gynecology, Zhejiang Provincial People's Hospital, Hangzhou, 310000, China.
Guangwu XiongDepartment of Obstetrics and Gynecology, Peking University International Hospital, Beijing, 100000, China.
Yuchong HuDepartment of Obstetrics and Gynecology, Inner Mongolia Autonomous Region People's Hospital, Hohhot, 010000, China.
Shikai LiuDepartment of Gynecology, Cangzhou Central Hospital, Cangzhou, 061000, China.
Jianwei ZhouDepartment of Obstetrics and Gynecology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, 310000, China.
Huafeng ShouDepartment of Obstetrics and Gynecology, Zhejiang Provincial People's Hospital, Hangzhou, 310000, China.
Lei LiDepartment of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, 100730, China. lileigh@163.com.

Funding

China Postdoctoral Science Foundation 2022T150066State Key Laboratory for Complex, Severe and Rare Diseases in Peking Union Medical College Hospital, by the Beijing Science and Technology Projects Z211100002921068the CAMS Innovation Fund for Medical Sciences (CIFMS) 2022-I2M-C&T-B-033the Key Research Project of Beijing Natural Science Foundation Z220013the National High Level Hospital Clinical Research Funding 2022-PUMCH-A-117, 2022-PUMCH-B-083, 2022-PUMCH-C-010, 2022-PUMCH-C-022 and 2022-PUMCH-D-003
6 · The paper itself

Abstract

objectivesIn this study, we aimed to validate the performance of the PAX1 and JAM3 methylation (PAX1

methodsThe triage performance of liquid-based cytology (LBC) and the PAX1

resultsIn total, 1851 participants had cervical histological outcomes and were included in the analysis. The sensitivity/specificity of the LBC test results with atypical squamous cells of undetermined significance or worse (LBC ≥ ASCUS) and the PAX1

conclusionsIn non-16/18 hrHPV(+) women, PAX1

Indexed as

Early Detection of CancerHuman Papillomavirus VirusesPaired Box Transcription FactorsPapillomavirus InfectionsTriageUterine Cervical DysplasiaUterine Cervical NeoplasmsChinaDNA MethylationFemaleHumansProspective StudiesSensitivity and SpecificityPaired Box Transcription FactorsPAX1 transcription factorCervical cancerCervical intraepithelial lesionsDNA methylationHuman papillomavirus DNA testsLiquid-based cytologyNon-16/18-type high-risk human papillomavirus infections

Identifiers

PMID39152491
PMCPMC11330154

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.